The Global Times reports that the number of patients infected with the novel coronavirus pneumonia (COVID-19) will likely peak during the second half of February in southern China, while nationwide, the expected high-point should occur in April, said Zhong Nanshan, the central government's top medical advisor.
- While new infections are reported daily outside of Central China's Hubei Province, where the outbreak's epicenter Wuhan is located, dropped for 13 consecutive days on Sunday.
- A statistics model suggested that by the end of February, nationwide infections will have reached 170,000 while actual data as of Monday indicates roughly 70,000, Zhong said on Monday.
- "It does not necessarily mean that it will fall immediately after reaching the peak. Reaching the peak refers to accumulated cases or new cases," the expert said, noting the number should peak in late February.
- Also, the peak does not suggest an inflection.
- When asked about the massive labor migration following the Spring Festival holidays, and if there would be another peak, Zhong said, "I think probably not," noting that authorities have adopted strict inspection and quarantine measures, making another outbreak unlikely.
- Zhong emphasized that Wuhan has a very high morbidity rate. Confirmed COVID-19 patients in the provincial capital make up 80 percent of the nationwide total, and 95 percent of the nationwide fatality rate.
- Zhong noted that if the problem in Wuhan is solved by separating healthy people from patients and dealing with a significant number of suspected patients, it would have a positive influence nationwide.
- Treating COVID-19 patients is more challenging than treating SARS patients as critically ill patients who do not receive timely treatment will suffer continuous damage. "But it does not mean there is no hope at all," Zhong said, noting that research teams have been working to find more effective antiviral drugs, including new progress with Traditional Chinese Medicine and exploring new treatment methods.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.